Skip to content

Study · Not a test of the peptide alone · 2023

8 results

The effects of weight-lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta-analysis of randomized controlled trials.

Jobanputra R, Sargeant JA, Almaqhawi A, Ahmad E, Arsenyadis F, Webb DR, Herring LY, Khunti K, Davies MJ, Yates T

Obesity reviews : an official journal of the International Association for the Study of Obesity31 Jan 2023Cited by 17 (Europe PMC)

PMID36721366 (opens in a new tab)DOI10.1111/obr.13553 (opens in a new tab)PepBankPUB-36721366
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

Weight-lowering pharmacotherapies provide an option for weight management; however, their effects on physical activity, function, and cardiorespiratory fitness are not fully understood. We conducted a systematic review and meta-analysis of randomized controlled trials to investigate the effect of licensed weight loss pharmacotherapies on physical activity, physical function, and cardiorespiratory fitness in individuals with obesity. Fourteen trials met our prespecified inclusion criteria: Five investigated liraglutide, four semaglutide, three naltrexone/bupropion, and two phentermine/topiramate. All 14 trials included a self-reported measure of physical function, with the pooled findings suggesting an improvement favoring the pharmacotherapy intervention groups (SMD: 0.27; 95% CI: 0.22 to 0.32) and effects generally consistent across different therapies. Results were also consistent when stratified by the two most commonly used measures: The Short-Form 36-Item Questionnaire (SF-36) (0.24; 0.17 to 0.32) and the Impact of Weight on Quality Of Life-Lite (IWQOL-Lite) (0.29; 0.23 to 0.35). Meta-regression confirmed a significant association between pharmacotherapy induced weight loss and improved physical function for IWQOL-Lite (p = 0.003). None of the studies reported a physical activity outcome, and only one study reported objectively measured cardiorespiratory fitness. Improvements in self-reported physical function were observed with weight loss therapy, but the effect on physical activity or objectively measured physical function and fitness could not be determined.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with obesity, pooled weight-lowering drugs (including liraglutide) improved self-reported physical function (SMD 0.27).

    In plain wordsIn adults with obesity, a pool of weight-loss drugs, including liraglutide, was linked to better self-reported physical function.

    Peptide
    Liraglutide
    Outcome
    IncreaseSelf-reported physical function (pooled)
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Whole body

    Measurements

    SMD
    0.27
    pooled

    Source sentences

    Summary
    All 14 trials included a self-reported measure of physical function, with the pooled findings suggesting an improvement favoring the pharmacotherapy intervention groups (SMD: 0.27; 95% CI: 0.22 to 0.32) and effects generally consistent across different therapies.
    1 context sentence
    Summary · context
    Fourteen trials met our prespecified inclusion criteria: Five investigated liraglutide, four semaglutide, three naltrexone/bupropion, and two phentermine/topiramate.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with obesity, pooled weight-lowering drugs (including liraglutide) improved physical function on the SF-36 (0.24).

    In plain wordsIn adults with obesity, a pool of weight-loss drugs, including liraglutide, was linked to better SF-36 physical function scores.

    Peptide
    Liraglutide
    Outcome
    IncreasePhysical function by SF-36 (pooled)
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Whole body

    Measurements

    SMD
    0.24
    SF-36

    Source sentences

    Summary
    Results were also consistent when stratified by the two most commonly used measures: The Short-Form 36-Item Questionnaire (SF-36) (0.24; 0.17 to 0.32) and the Impact of Weight on Quality Of Life-Lite (IWQOL-Lite) (0.29; 0.23 to 0.35).
    1 context sentence
    Summary · context
    Fourteen trials met our prespecified inclusion criteria: Five investigated liraglutide, four semaglutide, three naltrexone/bupropion, and two phentermine/topiramate.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with obesity, pooled weight-lowering drugs (including liraglutide) improved physical function on the IWQOL-Lite (0.29).

    In plain wordsIn adults with obesity, a pool of weight-loss drugs, including liraglutide, was linked to better IWQOL-Lite physical function scores.

    Peptide
    Liraglutide
    Outcome
    IncreasePhysical function by IWQOL-Lite (pooled)
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Whole body

    Measurements

    SMD
    0.29
    IWQOL-Lite

    Source sentences

    Summary
    Results were also consistent when stratified by the two most commonly used measures: The Short-Form 36-Item Questionnaire (SF-36) (0.24; 0.17 to 0.32) and the Impact of Weight on Quality Of Life-Lite (IWQOL-Lite) (0.29; 0.23 to 0.35).
    1 context sentence
    Summary · context
    Fourteen trials met our prespecified inclusion criteria: Five investigated liraglutide, four semaglutide, three naltrexone/bupropion, and two phentermine/topiramate.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneSystematic reviewOther

    In adults with obesity, drug-induced weight loss across pooled weight-lowering drugs (including liraglutide) was associated with better IWQOL-Lite physical function (p = 0.003).

    In plain wordsIn adults with obesity, more weight loss on a pool of weight-loss drugs, including liraglutide, was linked to better physical function.

    Peptide
    Liraglutide
    Outcome
    IncreaseAssociation of weight loss with physical function (meta-regression)
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Whole body

    Source sentences

    Summary
    Meta-regression confirmed a significant association between pharmacotherapy induced weight loss and improved physical function for IWQOL-Lite (p = 0.003).
    1 context sentence
    Summary · context
    Fourteen trials met our prespecified inclusion criteria: Five investigated liraglutide, four semaglutide, three naltrexone/bupropion, and two phentermine/topiramate.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with obesity, pooled weight-lowering drugs (including semaglutide) improved self-reported physical function (SMD 0.27).

    In plain wordsIn adults with obesity, a pool of weight-loss drugs, including semaglutide, was linked to better self-reported physical function.

    Peptide
    Semaglutide
    Outcome
    IncreaseSelf-reported physical function (pooled)
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Whole body

    Measurements

    SMD
    0.27
    pooled

    Source sentences

    Summary
    All 14 trials included a self-reported measure of physical function, with the pooled findings suggesting an improvement favoring the pharmacotherapy intervention groups (SMD: 0.27; 95% CI: 0.22 to 0.32) and effects generally consistent across different therapies.
    1 context sentence
    Summary · context
    Fourteen trials met our prespecified inclusion criteria: Five investigated liraglutide, four semaglutide, three naltrexone/bupropion, and two phentermine/topiramate.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  6. 06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with obesity, pooled weight-lowering drugs (including semaglutide) improved physical function on the SF-36 (0.24).

    In plain wordsIn adults with obesity, a pool of weight-loss drugs, including semaglutide, was linked to better SF-36 physical function scores.

    Peptide
    Semaglutide
    Outcome
    IncreasePhysical function by SF-36 (pooled)
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Whole body

    Measurements

    SMD
    0.24
    SF-36

    Source sentences

    Summary
    Results were also consistent when stratified by the two most commonly used measures: The Short-Form 36-Item Questionnaire (SF-36) (0.24; 0.17 to 0.32) and the Impact of Weight on Quality Of Life-Lite (IWQOL-Lite) (0.29; 0.23 to 0.35).
    1 context sentence
    Summary · context
    Fourteen trials met our prespecified inclusion criteria: Five investigated liraglutide, four semaglutide, three naltrexone/bupropion, and two phentermine/topiramate.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 07HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with obesity, pooled weight-lowering drugs (including semaglutide) improved physical function on the IWQOL-Lite (0.29).

    In plain wordsIn adults with obesity, a pool of weight-loss drugs, including semaglutide, was linked to better IWQOL-Lite physical function scores.

    Peptide
    Semaglutide
    Outcome
    IncreasePhysical function by IWQOL-Lite (pooled)
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Whole body

    Measurements

    SMD
    0.29
    IWQOL-Lite

    Source sentences

    Summary
    Results were also consistent when stratified by the two most commonly used measures: The Short-Form 36-Item Questionnaire (SF-36) (0.24; 0.17 to 0.32) and the Impact of Weight on Quality Of Life-Lite (IWQOL-Lite) (0.29; 0.23 to 0.35).
    1 context sentence
    Summary · context
    Fourteen trials met our prespecified inclusion criteria: Five investigated liraglutide, four semaglutide, three naltrexone/bupropion, and two phentermine/topiramate.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  8. 08HumanNot a test of Semaglutide aloneSystematic reviewOther

    In adults with obesity, drug-induced weight loss across pooled weight-lowering drugs (including semaglutide) was associated with better IWQOL-Lite physical function (p = 0.003).

    In plain wordsIn adults with obesity, more weight loss on a pool of weight-loss drugs, including semaglutide, was linked to better physical function.

    Peptide
    Semaglutide
    Outcome
    IncreaseAssociation of weight loss with physical function (meta-regression)
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Whole body

    Source sentences

    Summary
    Meta-regression confirmed a significant association between pharmacotherapy induced weight loss and improved physical function for IWQOL-Lite (p = 0.003).
    1 context sentence
    Summary · context
    Fourteen trials met our prespecified inclusion criteria: Five investigated liraglutide, four semaglutide, three naltrexone/bupropion, and two phentermine/topiramate.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.